

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

Investigating the Effect of Rosa damascene and Phenytoin Cream on pain and episiotomy wound healing in primiparous women

Protocol summary

Study aim

Determining and comparison of the average pain score on days 1, 5, 10 after delivery in two intervention groups (Rosa damascene cream and phenytoin cream) and the control group Determining and comparison of the average Reeda score on days 1, 5, 10 after delivery in two intervention groups (Rosa damascene cream and phenytoin cream) and the control group

Design

A triple blinded parallel phase 3 clinical trial study on 120 pregnant women who were divided into 2 intervention groups (Rosa damascene cream and phenytoin cream) and a control group (placebo) with The allocation ratio will be 1:1:1. All three groups will receive routine treatment.

Settings and conduct

Rosa damascene cream and placebo cream based on Vaseline prepared by a traditional medicine pharmacist, as well as phenytoin cream prepared by Amin Pharmaceutical Company at the Traditional Medicine Research Center will be filled in 60 gram white tubes with the same names as A, B and C. and will be provided to the researcher to conduct research. The researcher, the participant, the outcome assessor and the results analyzer (results are coded) and the data safety and monitoring committee will not know the contents of the tubes until the end of the review and the announcement of the results. On the 1th and 5th and 10th days of delivery, pain intensity and improvement of wound healing will be measured by Reeda and VAS questionnaires.

Participants/Inclusion and exclusion criteria

Normal pregnancy and delivery and absence of illness or drug use effective on wound healing

Intervention groups

Intervention group 1: Rosa damascene cream
Intervention group 2: Phenytoin cream Control group: placebo cream In all three groups, in addition to routine treatment, from the first day of delivery, every 8 hours

for 10 days in the episiotomy area.

Main outcome variables

pain intensity and improvement of wound healing

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220816055724N1**

Registration date: **2022-09-02, 1401/06/11**

Registration timing: **prospective**

Last update: **2022-09-02, 1401/06/11**

Update count: **0**

Registration date

2022-09-02, 1401/06/11

Registrant information

Name

Fereshteh Farzanazar

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 86 3417 3502

Email address

farzanazar@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-09-23, 1401/07/01

Expected recruitment end date

2023-02-20, 1401/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
Investigating the Effect of Rosa damascene and Phenytoin Cream on pain and episiotomy wound healing in primiparous women

Public title
The Effect of Rosa damascene and Phenytoin Cream on pain and episiotomy wound healing

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
 Normal pregnancy and delivery Having at least reading and writing literacy perimiparus Age between 15-45 Body mass index (after delivery) between 18.5-30 kilograms per square meter
Exclusion criteria:
 Gestational age 37-42 , Cephalic presentation, one alive fetuse suffering from diseases that interfere with wound healing (such as anemia, infection and wounds in the perineum, diabetes, blood pressure, skin, heart, kidney, lung diseases, coagulation disorder, immunodeficiency, hemophilia, disorder connective tissue, depression, malnutrition, mental illnesses, cancer) using drugs effective on wound healing by the mother (anticoagulants, antidepressants, antiepileptics), alcohol, smoking, glucocorticoids, immune system suppressors, antibiotics, and narcotics and psychotropic drugs, not doing The duration of rupture of the Amionitic membran is not more than 18 hours Non-instrumental vaginal delivery with medial and lateral episiotomy incision having a history of previous injury or surgery and visible lesions in the perineum (genital warts, hemorrhoids) and persistent constipation (according to the patient's statement) Spontaneous removal of the placenta

Age
From **15 years** old to **45 years** old

Gender
Female

Phase
3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size
Target sample size: **120**

Randomization (investigator's opinion)
Randomized

Randomization description
To create a randomization sequence or Random sequence generation, at first, each of the 120 volunteers who meet the criteria for entering the study are given codes from 001 to 120, then using a table of random

numbers and choosing the path from top to bottom and keeping in mind Numbers 001 to 040 for the intervention group of rose flower cream or A, numbers 041 to 080 for the intervention group of phenytoin cream or B, and numbers 081 to 120 for the control group or placebo cream or C, the researcher puts his hand on one of the numbers and It moves in the predetermined direction and records the obtained number and assigns it to different groups according to the default type. Then, for the second stage of allocation concealment, three batches of creams are prepared by the traditional medicine doctor in the laboratory in the same shape, color and smell with Vaseline base in each batch in the same 60 gram white tubes and with the name A is prepared for rose cream, B for phenytoin cream and C for placebo cream. In the third stage of randomization or implementation of the process, the participant in the study, the person who created the random sequence, the person who examined the participants in terms of entry and exit criteria and enrolled them in the study, and the person who participated He has allocated the manufacturers to groups, the person who performs the data analysis and the researcher does not know about the allocation of groups and the type of drug in the creams is also known only to the manufacturer, who will not inform others of the results until the end of the analysis.

Blinding (investigator's opinion)

Triple blinded

Blinding description

Rosa damascene cream and placebo cream based on Vaseline prepared by a traditional medicine pharmacist, as well as phenytoin cream prepared by Amin Pharmaceutical Company at the Traditional Medicine Research Center will be filled in 60 gram white tubes with the same names as A, B and C. and will be provided to the researcher to conduct research. The researcher, the participant, the outcome assessor and the results analyzer (the results are coded) and the data safety and monitoring committee will not know the contents of the tubes until the end of the study and the announcement of the results.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Arak University of Medical Sciences

Street address

Alamlhoda Aenue

City Arak Province Markazi Postal code ۳۸۱۹۶۹۳۳۴۰ Approval date 2022-06-26, 1401/04/05 Ethics committee reference number IR.ARAKMU.REC.1401.095	The effect of Rosa damascene cream, phenytoin and placebo on episiotomy Burning on days 1, 5 and 10 after delivery (day 1, 5 and 10 after intervention) Method of measurement check list
Health conditions studied <u>1</u> Description of health condition studied Pain ICD-10 code G89.18 ICD-10 code description Other acute postprocedural pain	<u>2</u> Description redness Timepoint The effect of Rosa damascene cream, phenytoin and placebo on episiotomy redness on days 1, 5 and 10 after delivery (day 1, 5 and 10 after intervention) Method of measurement check list
<u>2</u> Description of health condition studied wound healing ICD-10 code O90.1 ICD-10 code description Disruption of perineal obstetric wound	<u>3</u> Description wheal Timepoint The effect of Rosa damascene cream, phenytoin and placebo on episiotomy wheal on days 1, 5 and 10 after delivery (day 1, 5 and 10 after intervention) Method of measurement check list
Primary outcomes <u>1</u> Description episiotomy wound pain Timepoint The effect of Rosa damascene cream, phenytoin and placebo on episiotomy pain on days 1, 5 and 10 after delivery (day 1, 5 and 10 after intervention) Method of measurement Ruler method- Using the VAS questionnaire <u>2</u> Description Repair of episiotomy wound Timepoint The effect of Rosa damascene cream, phenytoin and placebo on episiotomy wound healing on days 1, 5 and 10 after delivery (day 1, 5 and 10 after intervention) Method of measurement Reeda questionnaire	Intervention groups <u>1</u> Description Intervention group: Rosa damascene cream. cream will be prepared by a traditional medicine pharmacist based on the formulation of Iranian traditional medicine books; In this way, after identifying and ensuring the authenticity of the raw material and some relevant quality factors, the components of the composition are standardized and the samples are controlled from a microbial point of view, and then the relevant cream will be prepared from the extract of this medicinal plant with Vaseline base and inside 60 gram tubes will be poured. These drugs will be prescribed to patients 3 times a day for 10 days. Category Treatment - Drugs <u>2</u> Description Intervention group: Phenytoin Cream. The cream is prepared by Amin Pharmaceutical Company and is prepared in the traditional medicine center by a traditional medicine pharmacist in 60 mg white tubes similar to other creams. These drugs will be prescribed 3 times a day for 10 days in the episiotomy area. Category Treatment - Drugs
Secondary outcomes <u>1</u> Description Drug side effects Timepoint	<u>3</u> Description

Control group: Placebo cream. Vaseline-based cream will be prepared similar to the creams of the intervention group and then will be poured into 60 gram tubes. This medicine will be prescribed 3 times a day for 10 days in the episiotomy area.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Arak Taleghani Hospital

Full name of responsible person

Mrs. Fatemeh Shabani

Street address

Emamkhomani Avenue

City

Arak

Province

Markazi

Postal code

3816149369

Phone

+98 86 3277 6063

Email

lt-taleghani@arakmu.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr Kamali

Street address

Sardasht mojtemepayambarazam

City

Arak

Province

Markazi

Postal code

3848176341

Phone

+98 86 3417 3639

Email

research@arakmu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Arak University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Fatemeh Shabani

Position

Faculty Member

Latest degree

Master

Other areas of specialty/work

Midwifery

Street address

Sardasht mojtemepayambarazam

City

Arak

Province

Markazi

Postal code

38481-7-6341

Phone

+98 86 3417 3520

Email

fatemeshabani@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr Mehdi Salehi

Position

Faculty Member

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

Sardasht mojtemepayambarazam

City

Arak

Province

Markazi

Postal code

38481-7-6341

Phone

+98 86 3417 3520

Email

daneshkadeha@arakmu.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Fatemeh Shabani

Position

Faculty Member

Latest degree

Master

Other areas of specialty/work

Midwifery

Street address

Sardasht mojtabepayambarazam

City

Arak

Province

Markazi

Postal code

38481-7-6341

Phone

+98 86 3417 3520

Email

fatemeshabani@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

It is a private data

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available

Title and more details about the data/document

-

When the data will become available and for how long

--

To whom data/document is available

--

Under which criteria data/document could be used

--

From where data/document is obtainable

--

What processes are involved for a request to access data/document

--

Comments

--